Sidekick and Pfizer launch digital therapeutics solution to tackle Atopic Dermatitis
Iceland-based international digital therapeutics innovator, Sidekick Health, has partnered with Pfizer Inc., one of the world’s premier innovative biopharmaceutical companies.
This news follows the $55 million Series B funding that Sidekick secured recently in Iceland’s biggest round in 2022. With this, the total funding raised by the company is now $75 million.
Partnership with Pfizer
As a part of the multimillion-dollar partnership, Sidekick and Pfizer will roll out their integrated digital therapeutics offering that will be launched first in the UK. It will be followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan later this year. This marks the next phase of a growing relationship to develop digital patient support programs globally, including expansion into 24 markets by 2024.
“We are extremely excited to be entering the next phase in our ongoing relationship with Pfizer,” commented Dr. Tryggvi Thorgeirsson, CEO and Co-Founder of Sidekick. “At Sidekick, it’s always been our ambition to help as many people as possible to make long-lasting improvements to their disease management, with the aim of improving people’s health outcomes and quality of life. Our work with Pfizer escalates our mission to bring digital therapeutics into the homes of people around the world.
Ana Paula Carvalho, Regional President, International Developed Markets, Inflammation & Immunology at Pfizer highlighted that “Autoimmune and chronic inflammatory diseases such as atopic dermatitis can be debilitating, disfiguring, and distressing, dramatically affecting what people living with the disease can do. At Pfizer, we recognize patient care goes beyond medical advances and we are proud to be working with Sidekick to put their technology in the hands of people who need it most. A holistic approach to treating the individual, not just the disease, is essential in order to advance the standard of care for patients and to empower them to live their best lives.”
Helps patients with Atopic Dermatitis
Sidekick was founded by in 2014 by Saemundur Oddsson and Tryggvi Thorgeirsson in Reykjavík. Its co-founders are passionate medical doctors on a mission to improve the health of humanity. Sidekick has offices in Berlin, Boston, Reykjavik and Stockholm.
The company has announced the launch of an integrated digital therapeutics solution to improve the outcomes of patients with Atopic Dermatitis (AD). AD is an inflammatory, pruritic, chronic, or chronically relapsing skin disease that affects up to 14% of adults worldwide. People living with moderate to severe AD often have to deal with constant and relentless itching, leading to sleep deprivation, increased stress and anxiety that affects the quality of their lives.
One of the challenges of effectively treating AD is that patients’ adherence to treatment tends to be low. Sidekick’s digital therapeutics platform addresses this using gamification principles and behavioural economics to deliver treatment through dynamic care pathways that help inspire lasting behavioral change, positively impacting health outcomes by addressing the same endpoints as traditional treatments.
Partnerships of Sidekick
Sidekick partners with the world’s most innovative companies across the healthcare spectrum. In 2019, the company entered into a strategic partnership with Bayer to provide digital therapeutics to patients with Peripheral Artery Disease (PAD). In 2020, it collaborated with the Icelandic government by providing remote triaging, monitoring and management of people infected with COVID-19.
